Vault-13

Elmind Capital, LP

NEW YORK, NY · CIK 2052213 · 13F filing filed 2026-08-14

SEC-registered investment adviser since 2024 · limited partnership

$398.0m reported value +13.0% vs Q1 2026
35positions
66.6%in top 10
6 new 9 added 6 reduced 5 sold out vs Q1 2026

Holdings, Q2 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 COGENT BIOSCIENCES INC COM COGT COGT 1,170,740 $45.3m11.38% 11.38% UnchangedShares held: Q3 2025 —, Q4 2025 1.2m, Q1 2026 1.2m, Q2 2026 1.2m
2 SYNDAX PHARMACEUTICALS INC COM SNDX SNDX 1,855,000 $40.6m10.19% 10.19% UnchangedShares held: Q3 2025 —, Q4 2025 1.9m, Q1 2026 1.9m, Q2 2026 1.9m
3 CELLDEX THERAPEUTICS INC NEW COM NEW CLDX CLDX 990,000 $36.8m9.25% 9.25% AddedShares held: Q3 2025 —, Q4 2025 865.0k, Q1 2026 865.0k, Q2 2026 990.0k +125.0k +125,000 14.4%
4 RELAY THERAPEUTICS INC COM RLAY RLAY 1,465,279 $27.4m6.89% 6.89% AddedShares held: Q3 2025 —, Q4 2025 536.9k, Q1 2026 536.9k, Q2 2026 1.5m +928.3k +928,333 172.9%
5 VAXCYTE INC COM PCVX PCVX 452,340 $26.3m6.61% 6.61% AddedShares held: Q3 2025 —, Q4 2025 291.5k, Q1 2026 316.5k, Q2 2026 452.3k +135.8k +135,840 42.9%
6 VERA THERAPEUTICS INC CL A VERA VERA 436,518 $18.7m4.71% 4.71% ReducedShares held: Q3 2025 —, Q4 2025 482.5k, Q1 2026 482.5k, Q2 2026 436.5k -46.0k -45,982 -9.5%
7 PHARVARIS N V COM PHVS PHVS 525,750 $18.2m4.57% 4.57% AddedShares held: Q3 2025 —, Q4 2025 475.8k, Q1 2026 475.8k, Q2 2026 525.8k +50.0k +50,000 10.5%
8 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 984,931 $18.1m4.55% 4.55% AddedShares held: Q3 2025 —, Q4 2025 858.6k, Q1 2026 534.9k, Q2 2026 984.9k +450.0k +450,000 84.1%
9 CYTOMX THERAPEUTICS INC COM CTMX CTMX 4,550,000 $17.1m4.29% 4.29% UnchangedShares held: Q3 2025 —, Q4 2025 700.0k, Q1 2026 4.5m, Q2 2026 4.5m
10 TRAVERE THERAPEUTICS INC COM TVTX TVTX 292,600 $16.6m4.18% 4.18% AddedShares held: Q3 2025 —, Q4 2025 110.0k, Q1 2026 177.6k, Q2 2026 292.6k +115.0k +115,000 64.8%
11 LEGEND BIOTECH CORP SPONSORED ADS LEGN LEGN 570,569 $16.5m4.14% 4.14% NewShares held: Q3 2025 —, Q4 2025 0, Q1 2026 0, Q2 2026 570.6k
12 BEAM THERAPEUTICS INC COM BEAM BEAM 476,338 $16.3m4.11% 4.11% UnchangedShares held: Q3 2025 —, Q4 2025 476.3k, Q1 2026 476.3k, Q2 2026 476.3k
13 CULLINAN THERAPEUTICS INC COM CGEM CGEM 690,000 $12.6m3.16% 3.16% AddedShares held: Q3 2025 —, Q4 2025 310.0k, Q1 2026 530.0k, Q2 2026 690.0k +160.0k +160,000 30.2%
14 NURIX THERAPEUTICS INC COM NRIX NRIX 460,000 $11.2m2.80% 2.80% UnchangedShares held: Q3 2025 —, Q4 2025 460.0k, Q1 2026 460.0k, Q2 2026 460.0k
15 KRYSTAL BIOTECH INC COM KRYS KRYS 22,000 $8.2m2.05% 2.05% UnchangedShares held: Q3 2025 —, Q4 2025 22.0k, Q1 2026 22.0k, Q2 2026 22.0k
16 UNITED THERAPEUTICS CORP DEL COM UTHR UTHR 15,000 $8.1m2.04% 2.04% UnchangedShares held: Q3 2025 —, Q4 2025 11.0k, Q1 2026 15.0k, Q2 2026 15.0k
17 SUMMIT THERAPEUTICS INC COM SMMT SMMT 493,820 $7.2m1.81% 1.81% NewShares held: Q3 2025 —, Q4 2025 0, Q1 2026 0, Q2 2026 493.8k
18 INSMED INC COM PAR $.01 INSM INSM 65,000 $6.9m1.74% 1.74% NewShares held: Q3 2025 —, Q4 2025 0, Q1 2026 0, Q2 2026 65.0k
19 BIOCRYST PHARMACEUTICALS INC COM BCRX BCRX 520,000 $5.2m1.31% 1.31% ReducedShares held: Q3 2025 —, Q4 2025 2.1m, Q1 2026 1.0m, Q2 2026 520.0k -480.0k -480,000 -48.0%
20 MBX BIOSCIENCES INC COM MBX MBX 91,000 $5.0m1.26% 1.26% ReducedShares held: Q3 2025 —, Q4 2025 211.0k, Q1 2026 211.0k, Q2 2026 91.0k -120.0k -120,000 -56.9%
21 PROTAGONIST THERAPEUTICS INC COM PTGX PTGX 38,000 $4.7m1.17% 1.17% UnchangedShares held: Q3 2025 —, Q4 2025 38.0k, Q1 2026 38.0k, Q2 2026 38.0k
22 UROGEN PHARMA LTD COM URGN URGN 120,000 $4.4m1.11% 1.11% ReducedShares held: Q3 2025 —, Q4 2025 100.0k, Q1 2026 220.0k, Q2 2026 120.0k -100.0k -100,000 -45.5%
23 DBV TECHNOLOGIES S A SPONSORED ADS DBVT DBVT 265,000 $4.3m1.09% 1.09% UnchangedShares held: Q3 2025 —, Q4 2025 0, Q1 2026 265.0k, Q2 2026 265.0k
24 ALUMIS INC COM ALMS ALMS 130,000 $3.7m0.92% 0.92% UnchangedShares held: Q3 2025 —, Q4 2025 0, Q1 2026 130.0k, Q2 2026 130.0k
25 SUPERNUS PHARMACEUTICALS INC COM SUPN SUPN 70,000 $3.3m0.82% 0.82% AddedShares held: Q3 2025 —, Q4 2025 20.0k, Q1 2026 20.0k, Q2 2026 70.0k +50.0k +50,000 250.0%
26 BIOMARIN PHARMACEUTICAL INC COM BMRN BMRN 47,000 $2.7m0.68% 0.68% UnchangedShares held: Q3 2025 —, Q4 2025 82.0k, Q1 2026 47.0k, Q2 2026 47.0k
27 IMMUNOCORE HLDGS PLC ADS IMCR IMCR 81,143 $2.6m0.65% 0.65% AddedShares held: Q3 2025 —, Q4 2025 58.2k, Q1 2026 58.2k, Q2 2026 81.1k +22.9k +22,895 39.3%
28 AMYLYX PHARMACEUTICALS INC COM AMLX AMLX 112,000 $2.0m0.51% 0.51% UnchangedShares held: Q3 2025 —, Q4 2025 112.0k, Q1 2026 112.0k, Q2 2026 112.0k
29 ALECTOR INC COM ALEC ALEC 900,000 $1.8m0.45% 0.45% UnchangedShares held: Q3 2025 —, Q4 2025 900.0k, Q1 2026 900.0k, Q2 2026 900.0k
30 SEPTERNA INC COM SEPN SEPN 49,444 $1.7m0.42% 0.42% NewShares held: Q3 2025 —, Q4 2025 0, Q1 2026 0, Q2 2026 49.4k
31 DESIGN THERAPEUTICS INC COM DSGN DSGN 107,900 $1.6m0.39% 0.39% ReducedShares held: Q3 2025 —, Q4 2025 207.9k, Q1 2026 207.9k, Q2 2026 107.9k -100.0k -100,000 -48.1%
32 SUTRO BIOPHARMA INC COM SHS STRO STRO 32,037 $1.1m0.27% 0.27% NewShares held: Q3 2025 —, Q4 2025 0, Q1 2026 0, Q2 2026 32.0k
33 WAVE LIFE SCIENCES LTD SHS 96663EUR 96663EUR 177,846 $1.0m0.26% 0.26% UnchangedShares held: Q3 2025 —, Q4 2025 447.8k, Q1 2026 177.8k, Q2 2026 177.8k
34 TYRA BIOSCIENCES INC COM TYRA TYRA 20,000 $638.8k0.16% 0.16% ReducedShares held: Q3 2025 —, Q4 2025 350.0k, Q1 2026 350.0k, Q2 2026 20.0k -330.0k -330,000 -94.3%
35 ENGENE THERAPEUTICS INC COM ENGN ENGN 210,000 $363.3k0.09% 0.09% NewShares held: Q3 2025 —, Q4 2025 0, Q1 2026 0, Q2 2026 210.0k

Sold out since Q1 2026

SecurityTickerShares held beforeValue then
KALVISTA PHARMACEUTICALS INC KALV KALV 1,021,300 $20.6m1.0m shares
CG ONCOLOGY INC CGON CGON 291,800 $19.7m291.8k shares
APELLIS PHARMACEUTICALS INC APLS APLS 50,000 $2.0m50.0k shares
ENGENE HOLDINGS INC 210,000 $1.4m210.0k shares
EDGEWISE THERAPEUTICS INC EWTX EWTX 10,000 $315.0k10.0k shares